Aptose Biosciences Inc.

Industry

  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
    • Specialty Pharmaceuticals

Other Names/Subsidiaries

  • GeneSense Technologies
  • Lorus Therapeutics Inc.
  • Aptose Biosciences U.S
  • Aptose Suisse
  • NuChem Pharmaceuticals
See more in Biomedtracker

Latest on Aptose Biosciences Inc.

Scrip

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

 
• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis Inks Four-Year Proteome Resear

Scrip

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

New data from Aptose Biosciences’ Phase I/II TUSCANY trial in newly diagnosed acute myeloid leukemia (AML) show patients receiving 40mg or 80mg of the once-daily, oral multi-kinase inhibitor tuspetini

Scrip

Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down

 
• By Mandy Jackson

Dozens of public biopharmaceutical companies have announced plans in 2025 to assess strategic alternatives after clinical trial setbacks or as cash stockpiles dwindled. Both ESSA Pharma and Elevation

Scrip

Hanmi/Aptose’s AML Contender Shows Early Promise

 
• By Jung Won Shin

A series of confirmed complete remissions at various doses in patients receiving Hanmi Pharmaceutical Co., Ltd. ’s in-house-developed innovative drug for acute myeloid leukemia (AML), HM43239, are mo